Answers are grounded in this paper and cite their sources.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by the promyelocytic leukemia-retinoic acid receptor alpha (PML::RARA) fusion, most commonly resulting from t(15;17).Despite substantial improvements in treatment outcomes, early hemorrhagic mortality remains a major challenge, particularly when the recognition and initiation of all-trans retinoic acid (ATRA) are delayed.Atypical presentations involving urinary symptoms may complicate early diagnosis when potentially serious hematologic findings coexist with more common clinical complaints.We report a 54-year-old man with Parkinson's disease transferred for the evaluation of left-sided flank and back pain associated with urination.He also reported lower-extremity bruising, gingival bleeding, oral discomfort, and subjective fever.Dipstick urinalysis demonstrated positive nitrites and moderate blood, raising concern for urinary tract pathology, although computed tomography showed no nephrolithiasis, hydronephrosis, or acute intra-abdominal inflammatory process.Complete blood count (CBC) revealed profound pancytopenia: white blood cell (WBC) count, 2.0 × 10³/µL; hemoglobin, 7.2 g/dL; and platelets, 7,000/µL.Peripheral blood smear demonstrated circulating blasts.Bone marrow examination showed greater than 95% cellularity with abnormal promyelocytic proliferation; fluorescence in situ hybridization (FISH) confirmed PML::RARA t(15;17).Despite fibrinogen of 528 mg/dL, severe thrombocytopenia and mucocutaneous bleeding signaled substantial hemorrhagic risk.ATRA and arsenic trioxide (ATO) induction therapy began on hospital day 3, with transfusion support and intensive monitoring.By day 6, hemoglobin increased to 9.3 g/dL and platelets to 37,000/µL during supportive and leukemia-directed treatment, although neutropenia persisted.This case emphasizes the complete blood count and peripheral blood smear as diagnostic pivots when urinary complaints coexist with unexplained bleeding and multilineage cytopenias.The encouraging early course highlights coordinated management while reinforcing guideline recommendations to initiate ATRA immediately once APL is suspected, before molecular confirmation.
No takes yet. Share an insight, caveat, or question.
Sanchez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: